| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 196.6MM | +9% |
| Gross Profit | 181.5MM | - |
| Cost Of Revenue | 15.2MM | -19% |
| Operating Income | -18.3MM | -52% |
| Operating Expenses | 199.8MM | - |
| Net Income | -25.9MM | -33% |
| R&D | 32MM | -19% |
| G&A | 30.4MM | -14% |
| Marketing | 93.8MM | +2% |
| Amortization | 43.6MM | +32% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
SANTA MONICA, Calif., April 11, 2024--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., today announced it will release its first quarter 2024 financial results before U.S. markets open on Thursday, May 9, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s business outlook.
ELV vs. GDRX: Which Stock Is the Better Value Option?
A full quarter of 2024 is behind us now, and it’s clear that we’re in the midst of another bullish run, similar to last year. The gains are substantial; markets reached a trough in October 2023, and the S&P 500 is up ~24.5% from that point while the NASDAQ has rebounded 29%. Year-to-date, the indexes are up 9% and 10%, respectively. And, while last year’s gains rested on the narrow base of mega-cap tech firms, the gains this year are built on a broader foundation, providing investors with more o
Insiders were net buyers of GoodRx Holdings, Inc.'s ( NASDAQ:GDRX ) stock during the past year. That is, insiders...
The prescription-drug upstart got an upgrade from Wall Street.
ELV vs. GDRX: Which Stock Is the Better Value Option?
The consensus price target hints at a 29.1% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SANTA MONICA, Calif., March 14, 2024--GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced Interim CEO Scott Wagner has extended his commitment to the Company. In addition, Stephen LeSieur and Adam Karol have notified GoodRx of their decision to resign from the Company’s Board of Directors, effective March 14, 2024 and March 22, 2024, respectively.
GoodRx Holdings, Inc. (GDRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does GoodRx Holdings, Inc. (GDRX) have what it takes to be a top stock pick for momentum investors? Let's find out.